ID Source | ID |
---|---|
PubMed CID | 665287 |
CHEMBL ID | 1433062 |
CHEBI ID | 107380 |
SCHEMBL ID | 13856424 |
Synonym |
---|
MLS-0015730.0001 |
CHEBI:107380 |
MLS002583455 |
(3ar,6as)-3-(2-chlorophenyl)-5-(2,5-dimethoxyphenyl)-3a,6a-dihydropyrrolo[3,4-d][1,2]oxazole-4,6-dione |
HMS2286O09 |
(3ar,6as)-3-(2-chlorophenyl)-5-(2,5-dimethoxyphenyl)-3a,6a-dihydropyrrolo[3,4-d]isoxazole-4,6-dione |
SCHEMBL13856424 |
CHEMBL1433062 |
Q27185687 |
AKOS032391415 |
Class | Description |
---|---|
pyrrolidines | Any of a class of heterocyclic amines having a saturated five-membered ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 12.5893 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 8.9125 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.7783 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 23.7359 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 23.7359 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 3.5481 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 29.9033 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 8.9125 | 0.0184 | 6.8060 | 14.1254 | AID624172 |
WRN | Homo sapiens (human) | Potency | 30.6667 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 12.9953 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 5.0119 | 0.0013 | 18.0743 | 39.8107 | AID926 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 31.6228 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 17.0961 | 0.5406 | 17.6392 | 96.1227 | AID720503 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 50.1187 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.6561 | 9.4520 | 25.1189 | AID927 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 18.8876 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 9.1015 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 10.1908 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 3.2708 | 0.0752 | 15.2253 | 39.8107 | AID485360; AID540279 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 44.6684 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 25.1189 | 1.5849 | 13.0043 | 25.1189 | AID927 |
phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 9.1941 | 0.0757 | 8.4742 | 29.0628 | AID602233; AID686980 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Estrogen receptor 1 | Homo sapiens (human) | IC50 (µMol) | 9.7849 | 2.1616 | 13.6892 | 26.3472 | AID713 |
DNA (cytosine-5)-methyltransferase 1 isoform b | Homo sapiens (human) | IC50 (µMol) | 4.3500 | 1.2900 | 8.7555 | 41.0000 | AID602386 |
estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 (µMol) | 26.2452 | 1.9109 | 8.3165 | 18.7976 | AID1060; AID733 |
tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 0.4690 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 0.8330 | 0.4000 | 9.3610 | 90.0000 | AID602374 |
tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 52.2000 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.4800 | 2.6449 | 8.3270 | AID624241 |
Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 100.0000 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
Tat | Human immunodeficiency virus 1 | IC50 (µMol) | 82.1290 | 0.9960 | 39.8009 | 100.0000 | AID1117361 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 8.2500 | 0.1000 | 12.7265 | 63.0000 | AID521 |
nuclear receptor subfamily 4 group A member 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 14.8560 | 14.8560 | 25.3537 | 34.6240 | AID748 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |